Background: Therapeutic plasma exchange (TPE) in steroid-unresponsive relapses of patients with multiple sclerosis (MS) is an established therapy with response rates of up to 70%. Immunoadsorption (IA) specifically removes immunoglobulins from the patient’s plasma. It is hypothesized that IA therapy might be better tolerated than and as effective as TPE in the treatment of MS relapses. Experiences with IA therapy of steroid-unresponsive MS relapses are limited. Methods: We report our experiences with IA therapy in a series of 10 patients with steroid-unresponsive MS relapses. Results: A marked to moderate clinical response with clear gain of function was observed in 66% of our patients. IA therapy was well tolerated. Conclusions: IA therapy is an effective and well-tolerated therapeutic option for steroid-unresponsive MS relapses.

1.
McDonald WI: Relapse, remission, and progression in multiple sclerosis. N Engl J Med 2000;343:1486–1487.
2.
Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, Selmaj K, Visser LH, Sorensen PS: EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005;12:939–946.
3.
Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M: Plasma exchange therapy in steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2009;28:108–115.
4.
Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–886.
5.
Ruprecht K, Klinker E, Dintelmann T, Rieckmann P, Gold R: Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004;63:1081–1083.
6.
Bennetto L, Totham A, Healy P, Massey E, Scolding N: Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system: a report of six cases. J Neurol 2004;251:1515–1521.
7.
Schilling S, Linker RA, Konig FB, Koziolek M, Bahr M, Muller GA, Paulus W, Gartner J, Bruck W, Chan A, Gold R: Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt 2006;77:430–438.
8.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
9.
Palm M, Behm E, Schmitt E, Buddenhagen F, Hitzschke B, Kracht M, Kundt G, Meyer-Rienecker H, Klinkmann H: Immunoadsorption and plasma exchange in multiple sclerosis: complement and plasma protein behaviour. Biomater Artif Cells Immobilization Biotechnol 1991;19:283–296.
10.
de Andres C, Anaya F, Gimenez-Roldan S: Plasma immunoadsorption treatment of malignant multiple sclerosis with severe and prolonged relapses. Rev Neurol 2000;30:601–605.
11.
Schneidewind JM, Winkler R, Ramlow W, Tiess M, Hertel U, Sehland D: Immunoadsorption – a new therapeutic possibility for multiple sclerosis? Transfus Sci 1998;19(suppl):59–63.
12.
Klingel R, Heibges A, Fassbender C: Plasma exchange and immunoadsorption for autoimmune neurologic diseases – current guidelines and future perspectives. Atheroscler suppl 2009;10:129–132.
13.
Pittock SJ, Reindl M, Achenbach S, Berger T, Bruck W, Konig F, Morales Y, Lassmann H, Bryant S, Moore SB, Keegan BM, Lucchinetti CF: Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations. Mult Scler 2007;13:7–16.
14.
Rauer S, Euler B, Reindl M, Berger T: Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006;77:739–742.
15.
Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.